Public Relations Specialist
About the job
- A bachelor's degree in Marketing, Communications, or Business Administration is required.
- One to two years of experience in public relations, influencer marketing, or digital communications is required; experience within the fast-moving consumer goods industry is preferred.
- Proven success in influencer relationship management, campaign execution, and performance analysis is required.
- A strong understanding of digital trends, social media platforms, and content dynamics is required.
- Excellent communication, negotiation, and stakeholder management skills are required.
- A creative mindset combined with strong analytical and strategic thinking abilities is required.
- Plan and execute influencer marketing and public relations activities across the organization.
- Develop and implement strategies and campaigns that enhance Limitless Naturals' visibility and brand reputation.
- Build and maintain strong relationships with influencers, opinion leaders, journalists, and digital content creators.
- Manage influencer selection, briefing, contracting, and performance analysis.
- Collaborate with the marketing team to ensure consistent and aligned messaging, and work closely with digital marketing, design, and public relations teams to maximize campaign reach and engagement.
- Manage and optimize customer relationship management tools and systems for influencer relationships, and track, analyze, and report campaign performance and return on investment.
- Support corporate campaigns and product communications through storytelling and creative digital collaborations.
- Experience within the fast-moving consumer goods industry.
About the company
EVA Pharma develops and manufactures affordable medicines for global markets, focusing on 12 therapeutic areas such as anti-infectives, metabolic health, oncology, and pediatrics. It operates four manufacturing facilities with a 5,000-strong team and produces over one million healthcare products daily. The company runs two regional research centers that use AI-driven prediction and mRNA R&D to develop biological products and first-of-its-kind capabilities in the Middle East and Africa. EVA Pharma distributes its products to more than 60 countries and seeks to expand access to high-quality medicines worldwide. Its differentiation comes from its scale, regional R&D capabilities, and commitment to sustainable access, aiming to meet pressing, unmet disease needs with reliable supply.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Al Sharikat, Egypt
Founded
1997
Get referred to Eva Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Egypt’s December 2024 insulin approval opens exportable manufacturing revenues and credibility with regulators.
- November 2025 EVA Pharma Oncology targets 22 million packs annually, with 11 more treatments planned.
- Access-heavy partnerships with Gilead, BeiGene, and Porton create multiple near-term revenue streams.
What critics are saying
- Gilead’s generic lenacapavir supply starts 2027, so execution delays destroy EVA Pharma’s moat.
- Oncology launches need Egypt market uptake; BRUKINSA, TEVIMBRA, and seven in-house products face entrenched competitors.
- Any FDA, EDA, or Gilead tech-transfer setback blocks EVA Pharma’s pivot into high-value biologics.
What makes Eva Pharma unique
- Egypt’s 2024 Lilly insulin approval proves EVA Pharma can localize complex biologics manufacturing.
- The 2024 Gilead lenacapavir license makes EVA Pharma Africa’s sole local generic producer.
- The 2025 BeiGene deal and 2025 Porton MOU extend EVA Pharma beyond generics into oncology and CAR-T.
Help us improve and share your feedback! Did you find this helpful?